Alliance Pharma plc reported preliminary earnings results for the year ended December 31, 2016. Group revenue for 2016 is expected to be more than double the prior year at £97.5 million (2015: £48.3 million). This has been driven by the transformational acquisition of the ex-Sinclair products in December 2015 and the continued strong performance of the original Alliance portfolio. Trading profit before tax is expected to be in line with the Board's expectations. Group sales were enhanced by approximately £4.2 million due to the weakening of Sterling, primarily against the Euro and US Dollar. However the effect on profits was much smaller due to the increases in cost of goods and operating costs denominated in these currencies. Full year free cash flow was approximately double last year at over £12 million (2015: £6.3 million). Net debt decreased from £79.0 million at 30 June 2016 to approximately £76.1 million as at 31 December 2016, despite adverse foreign exchange movements following the weakening of Sterling.